Observational studyResearch and practice in thrombosis and haemostasis2026
Safety of von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at delivery.
Observational study in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuraxial anesthesia (NA) constitutes a risk for patients with bleeding disorders, the main hemorrhagic adverse effect being spinal epidural hematoma. No clear recommendation has been issued concerning NA use for delivery in patients with von Willebrand disease (VWD) whose von Willebrand factor (VWF) levels have not been spontaneously corrected by the end of pregnancy. Objectives: This study describes the experience of 8 French hospital centers with NA use during delivery in these patients. Methods: Patients included in this study manifested still uncorrected VWF levels at the end of pregnancy and received NA for delivery together with VWF substitution to avoid the risk of hemorrhage associated with this type of anesthesia. Thirty-two patients participated in the study, accounting for 40 pregnancies in total. All VWD types were represented except for type 3. VWF, factor (F)VIII, fibrinogen and platelet levels were recorded before and at the end of pregnancy. The monitoring of VWF levels, the type of VWF ± FVIII substitution, and the doses administered were also noted. We additionally reviewed the literature concerning NA use at delivery in patients with VWD. Results: No spinal epidural hematoma or ecchymosis related to NA was observed in any of the 32 patients during the 40 deliveries. Conclusion: In conclusion, our results suggest that patients with VWD manifesting VWF levels not spontaneously corrected by the end of pregnancy could safely benefit from NA with closely monitored VWF substitution. Based on these results and national and international recommendations, we formulated proposals on how to manage these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.